Clinical trials: Recurrent Non-Small Cell Lung Carcinoma
Non-small Cell Lung Cancer
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
This multi-center, open label Phase II/III clinical study is performed in patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment or with non TKI-sensitizing mutation or patients with EGFR exon20ins…
- Trial name
- NCT05020769
- Testing
- SI-B001, Osimertinib
- Where
- 3 sites in China
- Volunteers
- 14 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Breast Cancer, Non-small Lung Cancer
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral GDC-0032 administered in combination with either docetaxel or with paclitaxel.
- Trial name
- NCT01862081
- Testing
- Docetaxel, GDC-0032, Paclitaxel
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 80 people
- Sponsor
- Genentech, Inc.
Relapsed or Advanced Non-small Cell Lung Cancer
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
To evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of Almonertinib combined with SHR-1701 in relapsed or advanced NSCLC To evaluate the efficacy of Almonertinib combined with SHR-1701 in the…
- Trial name
- NCT05503888
- Testing
- Almonertinib combined with SHR-1701, Almonertinib
- Volunteers
- 160 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
- Trial name
- NCT02695290
- Testing
- Afatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030641
- Testing
- oblimersen sodium, docetaxel
- Where
- 44 sites in United States, Canada and 1 more
- Sponsor
- Genta Incorporated
Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
This single arm study will assess the feasibility of using Avastin plus platinum-based chemotherapy (cisplatin-gemcitabine or carboplatin-paclitaxel) in patients with advanced or recurrent squamous non-small cell lung cancer who…
- Trial name
- NCT00404703
- Testing
- bevacizumab [Avastin], Platinum-based chemotherapy
- Where
- 25 sites in Australia, Belgium and 8 more
- Volunteers
- 37 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC
- Trial name
- NCT00850577
- Testing
- Paclitaxel, Carboplatin, CT-322
- Where
- 55 sites in United States, Brazil and 6 more
- Volunteers
- 255 people
- Sponsor
- Bristol-Myers Squibb
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
The purpose of this study is to determine the maximum dose that is safely tolerated of the experimental drug Rhenium Re 188 P2045.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Neoplasm Recurrence, Local
- Trial name
- NCT00100256
- Testing
- Rhenium (Re 188 P2045, BAY86-5284)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Andarix Pharmaceuticals
Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6.
- Conditions
- Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07807345
- Testing
- STRO-006, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 285 people
- Sponsor
- Sutro Biopharma, Inc.
Non-small Cell Lung Cancer
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
The study is being conducted to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate vs. pembrolizumab in treatment naïve subjects with programmed death-ligand 1(PD-L1)-positive recurrent or metastatic…
- Trial name
- NCT05042375
- Testing
- camrelizumab + famitinib, pembrolizumab, camrelizumab
- Where
- 80 sites in China
- Volunteers
- 450 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non Small Cell Lung Cancer
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
This multi-center, open label phase II clinical study is performed in patients with locally advanced or metastatic EGFR wild-type ALK wild-type non-small cell lung cancer progressed on prior anti-PD-1 mab ± platinum-based…
- Trial name
- NCT05020457
- Testing
- SI-B001, AP or TP, Docetaxel
- Where
- 6 sites in China
- Volunteers
- 69 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
This is a randomized, double-blind, single-dose, parallel-group study comparing pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth…
- Conditions
- Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
- Trial name
- NCT05110118
- Testing
- LY01008, Avastin
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Lung Cancer, Non-small Cell Lung Cancer
A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
This study is designed to establish biosimilarity of SB8, a proposed biosimilar product of bevacizumab, to EU-sourced bevacizumab, in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT02754882
- Testing
- Bevacizumab, SB8, Carboplatin
- Where
- 105 sites in Belarus, Georgia and 11 more
- Volunteers
- 763 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Non-small Cell Carcinoma, Adenocarcinoma of Lung
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
This 2-phase study will determine the safety of treating patients with non-small cell lung cancer with the genetically engineered HyperAcute-Lung cancer vaccine.
- Conditions
- Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma
- Trial name
- NCT00073398
- Testing
- Drug: Hyperacute Lung Cancer Cell Vaccine
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- NewLink Genetics Corporation
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Lung Cancer
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the side effects of lometrexol.
- Trial name
- NCT00033722
- Testing
- folic acid, lometrexol
- Where
- 7 sites in United States
- Sponsor
- Tularik
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC)…
- Conditions
- Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
- Trial name
- NCT05363280
- Testing
- AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
- Where
- 7 sites in United States, Spain
- Volunteers
- 80 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
This study is implemented in association with the study "J-TAIL-2" ; prospective multicenter observational study of atezolizumab in patients with unresectable, locally advanced or metastatic non-small cell lung cancer, UMIN study…
- Trial name
- NCT04818983
- Where
- 95 sites in Japan
- Volunteers
- 470 people
- Sponsor
- Chugai Pharmaceutical
Lung Cancer
DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have previously…
- Trial name
- NCT00005091
- Testing
- exatecan mesylate
- Where
- 6 sites in Finland, Germany and 3 more
- Sponsor
- Daiichi Pharmaceuticals
Non-small Cell Lung Carcinoma (NSCLC), Melanoma
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
The purpose of this study is to evaluate the safety and tolerability of humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 (CM-24 [MK-6018]), administered intravenously as monotherapy and in combination with…
- Conditions
- Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02346955
- Testing
- CM-24 (MK-6018), Pembrolizumab (MK-3475)
- Where
- 3 sites in United States, Israel
- Volunteers
- 27 people
- Sponsor
- Famewave Ltd.